Developing Innovative High-Impact Therapeutic Solutions that Address Major Unmet Needs in Healthcare

Learn More

Orchestra BioMed is a Healthcare Innovation Company

Orchestra BioMed is a biomedical innovation company focused on developing high-impact therapeutic solutions to address significant unmet needs in cardiovascular health and other areas. We specialize in developing novel therapies that are:

  • Designed to fit current clinical treatment paradigms and leverage the established procedural techniques well-known to interventional physicians; and
  • Based on the use as well as convergence of advanced medical technology, biopharmaceuticals, biomaterials-based drug delivery, and intelligent bioelectronic therapeutic algorithms

Our business model is designed to advance promising therapeutic solutions through development and aims to leverage strategic partnerships with established global commercial leaders to optimize commercialization and profitability. The Orchestra BioMed team of industry leaders has proven expertise in every phase of medtech and biopharma product development. Our primary focus on cardiovascular disease reflects our goal to rapidly advance disruptive solutions that will improve the standard of care for millions of patients worldwide.

Product Pipeline Overview

Advancing a deep, multi-asset pipeline of high-impact therapeutic solutions built around two technology platforms.

Learn More

News & Events

Orchestra BioMed™ Adds Seasoned Biotech Executive Pamela Yanchik Connealy to Board of Directors

March 3, 2020

Ms. Yanchik Connealy will serve as the Audit Committee Chair, strengthening Orchestra BioMed’s financial reporting capabilities

New Hope, PA - Orchestra BioMed, Inc. (“Orchestra BioMed” or the “Company”), a biomedical innovation company providing high-impact solutions for large unmet needs in procedure-based medicine, today announced the addition of experienced biotech executive Ms. Pamela Yanchik Connealy to its Board of Directors as Audit Committee chair. Ms. Connealy currently serves as chief financial officer of Immunovant (NASDAQ: IMVT) and brings over 30 years of experience in biotech and technology business operations, including driving operational, financial and human resources excellence, establishing operations to manage pipeline and leading biotech product launches.

Orchestra BioMedTM Secures $20 Million Financing Facility from Silicon Valley Bank

December 10, 2019

New York, NY – Orchestra BioMed, Inc. (“Orchestra BioMed” or the “Company”), a biomedical innovation company providing high-impact solutions for large unmet needs in procedure-based medicine, today announced that it has entered into a $20 million credit facility agreement with Silicon Valley Bank (SVB), the bank of the world’s most innovative companies and their investors. This agreement provides up to $20 million of new capital to the Company for development and general corporate purposes, with an initial up to $10 million draw available at Orchestra BioMed’s sole option during the next 12 months and the remainder available to the Company following the completion of certain milestones.

Read All News